Melane Sampson, Author at BioTuesdays

Developments

Oruka initiates dosing of first patient in Phase 1 trial of ORKA-001

Oruka Therapeutics (NASDAQ:ORKA) has announced the initiation of dosing of in its Phase 1 clinical trial of ORKA-001, a subcutaneously administered, half-life extended monoclonal antibody targeting IL-23p19. Inhibitors...

December 20, 2024

Executive Moves

Adicet appoints Julie Maltzman as CMO

Adicet Bio (NASDAQ:ACET) has appointed Julie Maltzman, MD, as chief medical officer (CMO), effective January 13, 2025. Adicet reports that Dr. Maltzman succeeds Dr. Francesco Galimi, who has completed his tenure with...

December 18, 2024

Developments

Silo initiates PK and tolerability study for non-opioid extended-release pain therapeutic

Silo Pharma (NASDAQ:SILO) has announced the initiation of a preclinical pharmacokinetic (PK) and tolerability study, in partnership with AmplifyBio, to assess Silo’s dissolvable, ketamine-based injectable implant, SP-26...

December 18, 2024

Feature

GRIN targeting rare pediatric neurological disorders with precision therapies

Closely-held GRIN Therapeutics, a Neurvati Neuroscience company, is advancing promising research and development of precision therapeutics for neurodevelopmental disorders, predominately affecting children from infancy...

December 17, 2024

Developments

Larimar reports positive initial data from OLE study of nomlabofusp in FA

Larimar Therapeutics (NASDAQ:LRMR) has announced positive initial results from its ongoing open-label extension (OLE) study evaluating daily subcutaneous injections of 25 mg of nomlabofusp, either self-administered or...

December 16, 2024

Executive Moves

Jeb Ledell joins KalVista as COO

KalVista Pharmaceuticals (NASDAQ:KALV) has announced that Jeb Ledell has been appointed as chief operating officer (COO). Mr. Ledell brings more than 20 years of leadership and operational excellence in the...

December 16, 2024

Developments

MindMed announces first patient dosed in Phase 3 study of LSD in GAD

MindMed (NASDAQ:MNMD) has announced that the first patient has been dosed in its Phase 3 Voyage study of MM120, an orally disintegrating tablet (ODT) and pharmaceutically optimized form of LSD, in generalized anxiety...

December 16, 2024

Developments

Fractyl reveals promising preclinical data for pancreatic gene therapy program

Fractyl Health (NASDAQ:GUTS) has announced that it will present new data from its RJVA-001 Rejuva Smart GLP-1 pancreatic gene therapy program for the treatment of obesity and type 2 diabetes (T2D) at the 22nd World...

December 12, 2024

Executive Moves

Rockwell names Jesse Neri as CFO

Rockwell Medical (NASDAQ:RMTI) announced the promotion of Jesse Neri to chief financial officer (CFO). Mr. Neri, formally Rockwell’s senior vice president of finance, joined the company in 2023, bringing more than 25...

December 12, 2024

Developments

Candel achieves primary endpoint in Phase 3 trial evaluating CAN-2409 in prostate cancer

Candel Therapeutics (NASDAQ:CADL) has announced results from its multicenter Phase 3 trial evaluating CAN-2409 viral immunotherapy in patients with localized prostate cancer. The study achieved its primary endpoint...

December 11, 2024

Author - Melane Sampson

Oruka initiates dosing of first patient in Phase 1 trial of ORKA-001

Adicet appoints Julie Maltzman as CMO

Silo initiates PK and tolerability study for non-opioid extended-release pain therapeutic

GRIN targeting rare pediatric neurological disorders with precision therapies

Larimar reports positive initial data from OLE study of nomlabofusp in FA

Jeb Ledell joins KalVista as COO

MindMed announces first patient dosed in Phase 3 study of LSD in GAD

Fractyl reveals promising preclinical data for pancreatic gene therapy program

Rockwell names Jesse Neri as CFO

Candel achieves primary endpoint in Phase 3 trial evaluating CAN-2409 in prostate cancer

General

More